Emricasan, a Caspase Inhibitor, for Treatment of Subjects With Decompensated NASH Cirrhosis

Status unconfirmed · Phase 2 · Has a placebo group

Conditions studied: Decompensated Cirrhosis

In brief

This is a multicenter, double-blind, randomized, placebo-controlled study to evaluate the safety and efficacy of emricasan in improving event-free survival based on a composite clinical endpoint (where all-cause mortality, new decompensation events, and MELD score progression are events) in subjects with decompensated NASH cirrhosis.

Key facts

Study ID
NCT03205345
Run by
Conatus Pharmaceuticals Inc.
People needed
210
Starts
2017-06-28
Expected to finish
2019-08-01
Last updated by the study team
2019-03-19

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.